2. Isotope-Labeled Compounds

Isotope-Labeled Compounds

Isotope-Labeled Compounds

PDF 37.01 MB

Isotope-labeled compounds are chemical substances in which some atoms in their molecules are replaced by isotope atoms. The range of stable isotope products can cover from gases to complex molecules. Isotope-labeled compounds could provide a site-specific investigation of structures, making molecules easily detectable by mass spectrometry and NMR, and maintaining the physico-chemical properties of the target molecule at the same time.

MCE isotope-labeled compounds are all stable isotope-labeled compounds and are non-radioactive labeled substances. MCE isotope-labeled compounds are unique tools for identifying and understanding biological and chemical processes. Stable isotope-labeled products are now getting more and more popular among scientists. The scope of application is gradually penetrating into various scientific fields, such as life sciences, food and medicine, agriculture, environment, geology, etc. Stable isotope-labeled compounds have a wide range of applications in the Life Science areas, such as Metabolomics, Proteomics, Clinical studies, Deuterium drugs, etc.

Isotope-Labeled Compounds (12441):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15381S
    Fingolimod phosphate-d4 1794828-93-5 98%
    Fingolimod phosphate-d4 is deuterium labeled FTY720 Phosphate.
    Fingolimod phosphate-d4
  • HY-15394S
    (Rac)-Rotigotine-d7 (hydrochloride) 3026226-88-7 98%
    (Rac)-Rotigotine-d7 (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.
    (Rac)-Rotigotine-d7 (hydrochloride)
  • HY-15408S
    Trelagliptin-13C,d3 2707203-34-5 98%
    Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin. Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).
    Trelagliptin-13C,d3
  • HY-15414S
    Vortioxetine-d8 2140316-62-5 98%
    Vortioxetine-d8 (Lu AA 21004-d8) is a deuterated version of Vortioxetine. Vortioxetine (Lu AA 21004) is an antagonist of 5-HT3A and 5-HT7 receptors (Ki: 3.7 nM, 19 nM) and an inhibitor of 5-hydroxytryptamine transporter (SERT) (Ki: 1.6 nM), as well as a 5-HT1A agonist and a partial 5-HT1B agonist (Ki: 15 nM, 33 nM).
    Vortioxetine-d8
  • HY-15431S
    Capivasertib-d4
    Capivasertib-d4 (AZd5363-d4) is the deuterium labeled Capivasertib (HY-15431). Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.
    Capivasertib-d4
  • HY-15494S
    Picropodophyllin-d3 1454782-81-0 98%
    Picropodophyllin-d3 (AXL1717-d3; Picropodophyllotoxin-d3; PPP-d3) is the deuterium labeled Picropodophyllin (HY-15494). Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
    Picropodophyllin-d3
  • HY-15498S
    Rimegepant-d4
    Rimegepant-d4 (BMS-927711-d4) is the deuterium labeled Rimegepant (HY-15498). Rimegepant (BMS-927711) is an orally bioavailable and blood-brain barrier permeable antagonist of CGRP and AMY1 receptors, with a pIC50 of 8.01 and a Ki of 0.027 nM for human CGRP receptors. Rimegepant antagonizes cAMP production induced by αCGRP, βCGRP and amylin at CGRP and AMY1 receptors in humans, rats and mice, as well as at rat AMY3 receptors. Rimegepant can be used in research related to migraine.
    Rimegepant-d4
  • HY-15552S
    Podofilox-d6 98%
    Podofilox-d6 is the deuterium labeled Podofilox. Podofilox (Podophyllotoxin) is a potent inhibitor of microtubule assembly and DNA topoisomerase II.
    Podofilox-d6
  • HY-15581S
    MMAD-d8 98.95%
    MMAD-d8D is a deuterated form of MMAD, which is a microtubule disrupting agent.
    MMAD-d8
  • HY-15602S
    Ledipasvir-d6 2050041-12-6 99.0%
    Ledipasvir-d6 is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM.
    Ledipasvir-d6
  • HY-15662S
    Tulathromycin A-d7 2734920-62-6 98%
    Tulathromycin A-d7 (Tulathromycin-d7) is deuterium labeled Tulathromycin A. Tulathromycin A (Tulathromycin), a macrolide antibiotic, inhibits protein synthesis (IC50=0.26 μM) by targeting bacterial ribosome. Tulathromycin A is used for the research of respiratory disease in cattle and swine. Immunomodulatory effects.
    Tulathromycin A-d7
  • HY-15728S
    Radotinib-d6 2754051-83-5 98%
    Radotinib-d6 is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases.
    Radotinib-d6
  • HY-159176
    Antitumor agent-183 2775428-94-7 98%
    Antitumor agent-183 (compound 3f) has antitumor activity with metabolic stability. Antitumor agent-183 inhibits cancer cell growth, with IC50s less than 5 nM for A549, HCT116, and HS578T cells. The albumin-bound nanoparticle formulation of Antitumor agent-183 has prolonged retention in the tumor tissues.
    Antitumor agent-183
  • HY-15917S
    DL-Dithiothreitol-d10 302912-05-6 98.4%
    DL-Dithiothreitol-d10 is the deuterated form of DL-Dithiothreitol. DL-Dithiothreitol (DTT) is a strong reductant with anti-disulfidptosis activity. When DL-Dithiothreitol is oxidized, it forms a stable six-membered ring with an internal disulfide bond.
    DL-Dithiothreitol-d10
  • HY-15926S
    ONPG-13C 864933-71-1 98%
    ONPG-13C is the 13C labeled ONPG. ONPG is a colorimetric and spectrophotometric substrate for detection of β-galactosidase activit.
    ONPG-13C
  • HY-160266
    THR-β agonist 7 2604229-32-3 98%
    THR-β agonist-1 (Example 2) is a THR-β agonist, with EC50 values of 52 nM and 1017 nM for THR-β and THR-α, respectively.
    THR-β agonist 7
  • HY-161447
    USP1-IN-8 3033480-77-9 98%
    USP1-IN-8 (Compound 16) is an inhibitor for ubiquitin specific peptidase 1 (USP1) and its cofactor UAF1, with IC50 ≤50 nM. USP1-IN-8 inhibits proliferation of MDA-MB-436 with IC50 ≤50 nM.
    USP1-IN-8
  • HY-16271S
    Kevetrin-13C2,15N3 hydrochloride 2300178-72-5 98%
    Kevetrin (hydrochloride)-13C2,15N3 is the 13C-labeled and 15N-labeled Kevetrin (hydrochloride). Kevetrin hydrochloride is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity.
    Kevetrin-13C2,15N3 hydrochloride
  • HY-16322S
    Minodronic acid-d4 1807367-80-1 98%
    Minodronic acid-d4 (YM-529-d4) is deuterium labeled Minodronic acid (HY-16322). Minodronic acid (YM-529) is an FPP synthase inhibitor with an IC50 of 3 nM, and also an antagonist of P2X2/3 receptors with an IC50 of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer.
    Minodronic acid-d4
  • HY-163587
    PRMT5-IN-39-d3 3034033-85-4 98%
    PRMT5-IN-39-d3 is the deuterated form of PRMT5-IN-39. PRMT5-IN-39-d3 is an orally active PRMT5 inhibitor and can be used for study of cancer.
    PRMT5-IN-39-d3